Economic evaluation of trifluridine/tipiracil (TT) versus nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastro-esophageal junction cancer (GEJC) in Canada

被引：0
|
作者：
Virik, Kiran
Wilson, Robert B.
机构：
[1] Queens Univ, Dept Med Oncol, Kingston, ON, Canada
[2] Univ NSW, Dept Surg, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
378
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The potential drug cost impact of nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) in Canada.
    Virik, Kiran
    Wilson, Robert B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer
    Morelli, Cristina
    Formica, Vincenzo
    Patrikidou, Anna
    Rofei, Michela
    Shiu, Kai Keen
    Riondino, Silvia
    Argiro, Renato
    Floris, Roberto
    Ferlosio, Amedeo
    Orlandi, Augusto
    Roselli, Mario
    Arkenau, Hendrik-Tobias
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (05) : 2072 - 2081
  • [3] Efficacy of Nivolumab for Advanced Refractory Esophageal and Gastro-Esophageal Junction Cancer: Systemic Review and Meta-Analysis
    Li, Tian
    Zou, Yuntao
    Li, Yiting
    Friedenberg, Frank
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S185 - S185
  • [4] HER2 AND OTHER BIOMARKER TESTING PATTERNS AMONG PATIENTS WITH ADVANCED GASTRIC CANCER (GC) OR GASTRIC ESOPHAGEAL JUNCTION CANCER (GEJC)
    Mehta, S.
    Herms, L.
    Chou, L. N.
    Lam, C. K.
    Kwong, W. J.
    Cosgrove, D.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S497 - S497
  • [5] Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial
    Cheng, Xiangdong
    Xu, Zhiyuan
    Hu, Can
    Zhang, Yanqiang
    Pengfei, Yu
    Du, Yian
    Yang, Litao
    Zhang, Ruolan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Safety Profile of Nivolumab for Advanced Refractory Esophageal and Gastro-Esophageal Junction Cancer: Systemic Review and Meta-Analysis
    Zou, Yuntao
    Li, Tian
    Li, Yiting
    Friedenberg, Frank
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S158 - S158
  • [7] DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS
    Hall, J.
    Khela, K.
    Bertwistle, D.
    Xiao, H.
    [J]. VALUE IN HEALTH, 2020, 23 : S482 - S483
  • [8] Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
    Van Cutsem, E.
    Hochster, H.
    Shitara, K.
    Mayer, R.
    Ohtsu, A.
    Falcone, A.
    Yoshino, T.
    Doi, T.
    Ilson, D. H.
    Arkenau, H-T
    George, B.
    Benhadji, K. A.
    Makris, L.
    Tabernero, J.
    [J]. ESMO OPEN, 2022, 7 (06)
  • [9] Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
    Gullo, Irene
    Grillo, Federica
    Molinaro, Luca
    Fassan, Matteo
    De Silvestri, Annalisa
    Tinelli, Carmine
    Rugge, Massimo
    Fiocca, Roberto
    Mastracci, Luca
    [J]. ENDOSCOPY INTERNATIONAL OPEN, 2015, 3 (02) : E165 - E170
  • [10] ECONOMIC EVALUATION OF TRIFLURIDINE AND TIPIRACIL HYDROCHLORIDE IN THE TREATMENT OF METASTATIC GASTRIC CANCER IN THE BRAZILIAN PRIVATE HEALTH CARE SECTOR
    de Vasconcellos, Festa J.
    Albuquerque, S.
    Mardegan, L.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S109 - S109
12345